At a glance
- Originator Celltech Group
- Class Antifungals
- Mechanism of Action Protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 12 Dec 2003 Discontinued - Preclinical for Mycoses in United Kingdom (unspecified route)
- 08 Dec 2003 The integration of Oxford GlycoSciences into Celltech Group has been completed
- 31 Jul 2003 Oxford GlycoSciences has been acquired by Celltech Group